Beam Therapeutics Inc.(BEAM)Earnings, Financials & Key RatiosBeam Therapeutics Inc. (BEAM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on non-recurring revenue and a consistent quarterly cash burn exceeding $80 million present significant risks to long-term capital preservation.
Beam Therapeutics Inc. (BEAM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Beam Therapeutics Inc. (BEAM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.91vs $0.87-4.6% | $32Mvs $11M+189.1% |
| Q1 2026 | Feb 24, 2026 | $0.10vs $1.13+91.2% | $114Mvs $12M+877.9% |
| Q4 2025 | Nov 4, 2025 | $1.10vs $0.98-12.2% | $10Mvs $13M-26.6% |
| Q3 2025 | Aug 5, 2025 | $1.00vs $1.04+3.8% | $8Mvs $12M-26.6% |
Recent stock market news and headlines for Beam Therapeutics Inc. (BEAM)
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
Key metrics vs top competitors for Beam Therapeutics Inc. (BEAM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.92 | $3.9B | -46.81 | 120.01% | -57.24% | -8.11% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $3.99 | $720.66M | -2.96 | 55.28% | -4917.55% | -188.82% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — |
Beam Therapeutics Inc. (BEAM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Beam Therapeutics Inc. (BEAM) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 5, 2026·SEC
Feb 24, 2026·SEC
Get notified when BEAM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Beam Therapeutics Inc. (BEAM) stock FAQ — growth, dividends, profitability & financials explained
Beam Therapeutics Inc. (BEAM) reported $132.3M in revenue for fiscal year 2025.
Beam Therapeutics Inc. (BEAM) grew revenue by 120.0% over the past year. This is strong growth.
Beam Therapeutics Inc. (BEAM) reported a net loss of $65.0M for fiscal year 2025.
Beam Therapeutics Inc. (BEAM) has a return on equity (ROE) of -8.1%. Negative ROE indicates the company is unprofitable.
Beam Therapeutics Inc. (BEAM) had negative free cash flow of $383.8M in fiscal year 2025, likely due to heavy capital investments.
